Monitor ASH 2026 presentations (December 12-15) for updated LOTIS-7 and LOTIS-5 data, which could inform regulatory and compendia pathways. The financial restructuring removes near-term liquidity risk but dilution from the PIPE and warrants is a factor. Watch for FDA feedback on the LOTIS-5 sBLA and potential full approval.
Drug in focus
ADCT drug pipeline →ZYNLONTA
◆ Mixed Named in this 8-K- Impact
- Phase
- Approved (accelerated approval); Phase 3 confirmatory (LOTIS-5) completed; Phase 1b combination (LOTIS-7) ongoing
- Time to market
- Already on the market (FDA accelerated approval April 2021). Path to full FDA approval is uncertain after LOTIS-5 safety issues. Japan decision timeline is not specified.
- Next catalyst
- None dated
What to watchWatch the 68th ASH Annual Meeting (December 5-8, 2026) where multiple ZYNLONTA abstracts will be presented, including updated LOTIS-7 combination data and potentially the full LOTIS-5 dataset. Also monitor the Japan marketing authorization decision by Tanabe Pharma (filed October 29, 2026) and any FDA guidance on the path to full approval. The stock trades near $1.51 with a 52-week range of $0.78-$4.98, reflecting deep uncertainty around the regulatory path.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $1.67entry
- T+1 · 7d ago −9.58%α −9.21% · $1.51
- T+5 · 16h ago −25.15%α −23.46% · $1.25
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ADC Therapeutics reported Q3 2026 net product revenue of $21.0M, up 33% YoY from $15.8M, and a GAAP net loss of $0.16 per share, narrowing from a $0.30 loss a year ago. The company highlighted a strategic financial restructuring that included an $86.6M PIPE, debt reduction, and an extended cash runway into 2029, alongside upcoming ASH presentations for ZYNLONTA.
Key Financial Metrics
Key Facts
- Q3 2026 net product revenue was $21.0M, up from $15.8M in Q3 2025, a 33% increase.
- GAAP net loss per share was $0.16, compared to $0.30 in Q3 2025.
- Adjusted net loss per share was $0.06, compared to $0.19 in Q3 2025.
- Cash and cash equivalents were $189.2M as of September 30, 2026, with expected cash runway into 2029.
- In October 2026, the company completed an $86.6M PIPE financing, issued 12.9M shares and 48M warrants, and reduced senior secured loan principal by $68.5M to $50M.
- Multiple ZYNLONTA abstracts accepted for ASH 2026, including five oral presentations.
- Japanese partner Tanabe Pharma submitted a marketing authorization application for ZYNLONTA in Japan.
Financial Impact
Q3 product revenue $21.0M (up 33% YoY); GAAP net loss $25.3M; cash $189.2M; PIPE $86.6M; debt reduced by $68.5M
Risk Factors
- FDA raised serious concerns about LOTIS-5 trial results at a recent pre-sBLA submission meeting, creating regulatory uncertainty.
- Dilution from 12.9M new shares and 48M warrants issued in the PIPE.
- Company still operating at a net loss with $74.8M net loss for nine months.
- Reliance on ZYNLONTA as sole marketed product; pipeline otherwise limited.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-071899 |
| Document: adc-20261109.htm | 0001628280-26-071899 |
| Document: 0001628280-26-071899-index-headers.html | 0001628280-26-071899 |
| Document: 0001628280-26-071899-index.html | 0001628280-26-071899 |
| Document: 0001628280-26-071899.txt | 0001628280-26-071899 |
| 8-K Data (Synthetic) | 0001628280-26-071899 |
Track record
14 reports on ADCT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $1.41 Now $1.25 −11.35% settles Dec 15
- Nov 9, 20267d ago S-3 Neutral 3/10 Entry $1.51 Now $1.25 −17.22% settles Dec 9
- Nov 9, 20267d ago 8-K Neutral 4/10 Viewing Entry $1.67 Now $1.25 −25.15% settles Dec 8
- Nov 4, 202612d ago 8-K Mixed 6/10 Entry $1.64 Now $1.25 −23.78% settles Dec 4
- Nov 3, 202613d ago S-4 Neutral 3/10 Entry $1.72 Now $1.25 −27.33% settles Dec 3
- Oct 29, 202618d ago SC 13G Neutral 4/10 Entry $1.53 Now $1.25 −18.30% settles Nov 30
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $1.70 to $1.51 Now $1.25 −26.47% ▼ −11.18% −7.57% vs SPY
- Aug 6, 202614w ago Press Release Neutral 1/10 Entry $1.13 to $1.32 Now $1.25 +10.62% ▲ +16.81% +16.21% vs SPY
- Jul 2, 202619w ago 8-K Neutral 2/10 Entry $1.19 to $1.11 Now $1.25 +5.04% ▼ −6.72% −6.31% vs SPY
- Jun 3, 202623w ago 8-K Mixed 6/10 Entry $1.32 to $1.19 Now $1.25 −5.30% ▼ −9.85% −8.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers